Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome

scientific article published on 23 November 2015

Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2015PLoSO..1043393K
P356DOI10.1371/JOURNAL.PONE.0143393
P932PMC publication ID4658115
P698PubMed publication ID26600308
P5875ResearchGate publication ID284713002

P50authorKristi AlnekQ115189670
Kalle KisandQ47869143
Raivo UiboQ20089700
P2093author name stringLiina Vahter
Katrin Gross-Paju
Karin Kannel
P2860cites workSynthesis and release of B-lymphocyte stimulator from myeloid cellsQ73335981
Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunityQ81261843
BAFF is elevated in serum of patients with Wegener's granulomatosisQ81389227
Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody productionQ82993591
Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activityQ83366546
Pathogenesis of Sjögren's syndromeQ84149203
Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapseQ84243273
Serum BAFF and APRIL might be associated with disease activity and kidney damage in patients with anti-glomerular basement membrane diseaseQ85895154
Temporal evolution of remission following multiple sclerosis relapse and predictors of outcomeQ43575541
Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseasesQ45052751
A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responsesQ45302161
Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseasesQ45370998
Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndromeQ46940748
Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosisQ47274470
Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse.Q47705615
Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.Q50944222
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.Q51027456
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.Q51890331
Serum BAFF levels and skin mRNA expression in patients with Behçet's disease.Q54506434
Relapses in multiple sclerosis are age- and time-dependentQ59121723
Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluidQ59543689
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)Q22241644
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Q22252938
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphomaQ24646563
Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptorsQ28254182
Body fluid biomarkers in multiple sclerosisQ28303860
T cells, cytokines, and autoantigens in multiple sclerosis.Q30680147
Immune thrombocytopenia and B-cell-activating factor/a proliferation-inducing ligandQ33407661
Impact of multiple sclerosis relapses on progression diminishes with timeQ33898204
Treating multiple sclerosis with monoclonal antibodies: a 2013 updateQ34330211
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammationQ36161486
Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseasesQ36703792
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challengesQ36761844
Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophilsQ37043905
Overlapping and distinct mechanisms of action of multiple sclerosis therapies.Q37772310
Humoral autoimmunity in multiple sclerosisQ37785326
Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.Q38069890
The BAFF/APRIL system in SLE pathogenesis.Q38194895
Serum BAFF expression in patients with myasthenia gravis.Q38500219
G-CSF-stimulated neutrophils are a prominent source of functional BLySQ41818295
Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.Q42503142
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trialQ42647640
Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white populationQ42863405
Disease-modifying therapy in multiple sclerosis: update and clinical implicationsQ43414869
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue11
P407language of work or nameEnglishQ1860
P304page(s)e0143393
P577publication date2015-11-23
P1433published inPLOS OneQ564954
P1476titleChanges in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome
P478volume10

Reverse relations

cites work (P2860)
Q36005239Analysis of Associations of Human BAFF Gene Polymorphisms with Autoimmune Thyroid Diseases.
Q104479846B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Q49874476B-Cell Therapies in Multiple Sclerosis
Q38984981Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases
Q90706043Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?
Q87984753Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies
Q93006147High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection
Q39119839Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Q40623713Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients
Q48053281Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.
Q51668292Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-β Therapy in Multiple Sclerosis Patients.

Search more.